Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsJeffrey P Nadler
University of South Florida, College of Medicine, Tampa, Florida, USA
BMC Infect Dis 3:10. 2003
..Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared to APV 1200 mg BID (APV1200)...
HAART at 10: an interview with Joseph GatheJoseph Gathe
Donald R. Watkins Memorial Foundation, Houston, Texas, USA
Res Initiat Treat Action 11:46-8. 2005
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeksJoseph Gathe
Therapeutic Concepts, Houston, TX, USA
J Acquir Immune Defic Syndr 50:474-81. 2009
..Study M05-730 compared LPV/r tablets dosed once daily vs. twice daily in antiretroviral-naive subjects...
- Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients
Joseph Gathe
Therapeutic Concepts, Houston, Texas, USA
Antivir Ther 16:759-69. 2011
..This study (VERxVE) compared the efficacy and safety of the new nevirapine extended-release (NVP XR) formulation dosed once daily with NVP immediate release (IR) twice daily in treatment-naive patients...
- Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center
Joseph Gathe
Therapeutic Concepts, Houston, TX 77004, USA
Curr Med Res Opin 24:769-73. 2008
....
- Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients
Joseph C Gathe
Therapeutic Concepts, 4900 Fannin Street, Houston, TX 77004, USA
AIDS Res Hum Retroviruses 23:216-23. 2007
..The 500 mg/200 mg dose achieved the best efficacy, safety, and pharmacokinetic profile in this highly treatment-experienced population and was selected for the pivotal phase 3 studies...
- Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial
Joseph Gathe
Therapeutic Concepts, Houston, TX 77004, USA
Clin Infect Dis 43:1337-46. 2006
....
- Adherence and potency with antiretroviral therapy: a combination for success
Joseph Gathe
Therapeutic Concepts, Houston, Texas 77004, USA
J Acquir Immune Defic Syndr 34:S118-22. 2003
- Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir
Joseph Gathe
Baylor College of Medicine, Houston, Texas, USA
J Acquir Immune Defic Syndr 31:399-403. 2002
..CONCLUSIONS: The antiviral efficacy of a triple combination regimen containing once-daily didanosine EC is similar to that of a reference triple combination regimen...
- SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
Joseph C Gathe
Therapeutic Concepts, P.A, Houston, Texas, USA
AIDS 18:1529-37. 2004
..CONCLUSION: As a first choice protease inhibitor with a low daily pill burden, FPV/r QD was well tolerated and provided potent, durable antiviral suppression...
- Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
Joseph C Gathe
Therapeutic Concepts, P.A, Houston, Texas, USA
Clin Ther 28:745-54. 2006
..Adverse events had generally developed by 48 weeks of therapy and did not occur at a higher frequency through 120 weeks of treatment...
- Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults
Rosa F Yeh
University of Houston, College of Pharmacy, Houston, TX, USA
J Int Assoc Physicians AIDS Care (Chic) 9:273-7. 2010
..3% vs3.3%; P = .004). Quality-of-life measures, tolerability, and diarrhea improved with the LPV/r tablet formulation compared to SGC in HIV-positive patients not receiving other antiretroviral therapy (ART)...
- Cord blood stem cell therapy for acquired immune deficiency syndrome
Gabriel Gonzalez
Department of Genetics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Stem Cells Dev 18:1-2. 2009
..Here we suggest that public cord blood repositories are likely to contain CCR5 homozygous units that could be used as a therapy for HIV-infected individuals...
- A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen
Margaret A Johnson
Royal Free Center for HIV Medicine, London, United Kingdom
J Acquir Immune Defic Syndr 43:153-60. 2006
..Both regimens were relatively well tolerated, and no LPV or TDF resistance was observed...
- Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens
I Chan Huang
University of Florida, Gainesville, USA
Antivir Ther 13:15-25. 2008
..This study assesses the influence of adverse events (AEs) on health-related quality of life (HRQOL) and change in HRQOL in patients treated with TPV/r versus CPI/r regimens...
- Antiretroviral rounds. Resistance: what you don't know--can it hurt you?
Joseph C Gathe
AIDS Clin Care 20:51-2. 2008
- Impact of resistance to antiretroviral therapy in the minority community
Allen E Rodriguez
University of Miami School of Medicine, Miami, Florida, USA
AIDS Read 14:S9-11. 2004
....
- Beyond efficacy: the impact of combination antiretroviral therapy on quality of life
Paul E Sax
Brigham and Women s Hospital, Division of Infectious Diseases, 75 Francis Street, PBB A 4, Boston, Massachusetts 02115, USA
AIDS Patient Care STDS 19:563-76. 2005
..As long as the virologic activity of these newer PIs is comparable to that of existing options, differentiating features beyond efficacy are important in the choice of an appropriate treatment regimen for patients with HIV...
